U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H18ClN5O2
Molecular Weight 359.81
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-4800567

SMILES

NC1=C2C(COC3=CC(Cl)=CC=C3)=NN(C4CCOCC4)C2=NC=N1

InChI

InChIKey=AUMDBEHGJRZSOO-UHFFFAOYSA-N
InChI=1S/C17H18ClN5O2/c18-11-2-1-3-13(8-11)25-9-14-15-16(19)20-10-21-17(15)23(22-14)12-4-6-24-7-5-12/h1-3,8,10,12H,4-7,9H2,(H2,19,20,21)

HIDE SMILES / InChI

Molecular Formula C17H18ClN5O2
Molecular Weight 359.81
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

PF 4800567 is a drug developed by Pfizer which acts as a selective potent inhibitor of CK1epsilon (IC(50) = 32 nM) with greater than 20-fold selectivity over CK1delta, and has mainly been used in the study of the casein kinase 1 enzymes in the regulation of circadian rhythm, as well as showing potential neuroprotective effects. PF 4800567 was found in animal studies to enhance responses to certain drugs of abuse such as methamphetamine and fentanyl, which suggests a role for CK1-ε in negative regulation of sensitivity to stimulant and opioid drugs.

CNS Activity

Curator's Comment: Mice harboring a null allele of Csnk1e showed an increase in locomotor activity following MA administration. Consistent with this result, coadministration of a PF-4800567 increased the locomotor stimulant response to both MA and fentanyl.

Originator

Curator's Comment: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
32.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation.
2011 Jun 2
Csnk1e is a genetic regulator of sensitivity to psychostimulants and opioids.
2012 Mar
Patents

Sample Use Guides

Mice: 40 mg/kg, i.p.
Route of Administration: Intraperitoneal
A significant lengthening of the period was observed at 1 uM PF 4800567 (approximately 10-fold CK1ε IC50; approximately 0.5- fold CK1δ IC50) in WT (0.9 ± 0.13 h increase in period) but not Ck1ε −/− -derived primary lung fibroblast cells (0.3 ± 0.3 h).
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:36:15 UTC 2023
Edited
by admin
on Sat Dec 16 17:36:15 UTC 2023
Record UNII
GEE72DRC63
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-4800567
Code English
1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[(3-chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-
Systematic Name English
PF4800567
Code English
3-[(3-Chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Systematic Name English
Code System Code Type Description
CAS
1188296-52-7
Created by admin on Sat Dec 16 17:36:15 UTC 2023 , Edited by admin on Sat Dec 16 17:36:15 UTC 2023
PRIMARY
WIKIPEDIA
PF-4800567
Created by admin on Sat Dec 16 17:36:15 UTC 2023 , Edited by admin on Sat Dec 16 17:36:15 UTC 2023
PRIMARY
PUBCHEM
53472153
Created by admin on Sat Dec 16 17:36:15 UTC 2023 , Edited by admin on Sat Dec 16 17:36:15 UTC 2023
PRIMARY
FDA UNII
GEE72DRC63
Created by admin on Sat Dec 16 17:36:15 UTC 2023 , Edited by admin on Sat Dec 16 17:36:15 UTC 2023
PRIMARY
EPA CompTox
DTXSID20703849
Created by admin on Sat Dec 16 17:36:15 UTC 2023 , Edited by admin on Sat Dec 16 17:36:15 UTC 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT